$175.58
4.062.37%
At close: -
$175.00
-0.58-0.33%
After Hours: 6:22 PM EDT
Comments
Loading...
Latest news for AbbVie (NYSE:ABBV) Stock
AbbVie Stock (NYSE: ABBV)
Categories: All
Thursday, December 19, 2024
Tuesday, December 17, 2024
Friday, December 13, 2024
Tuesday, December 10, 2024
Monday, December 09, 2024
- CNBC Halftime Report Final Trades: AbbVie, Ve...
- AbbVie And Genmab A/S Present Two Data Analys...
- Check Out What Whales Are Doing With ABBV
- AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
- AbbVie Announces Topline Results For The Phas...
- Reported Saturday, AbbVie Unveils Phase 1b/2 ...
- Reported Sunday, AbbVie's Emotional Impact Re...
Wednesday, December 04, 2024
Tuesday, December 03, 2024
Friday, November 29, 2024
Tuesday, November 26, 2024
Monday, November 25, 2024
Friday, November 22, 2024
Wednesday, November 20, 2024
Monday, November 18, 2024
Sunday, November 17, 2024
Friday, November 15, 2024
Wednesday, November 13, 2024
Tuesday, November 12, 2024
- Citigroup Maintains Buy on AbbVie, Lowers Pri...
- AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
- Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
- BMO Capital Maintains Outperform on AbbVie, L...
- Navigating 14 Analyst Ratings For AbbVie
- Morgan Stanley Maintains Overweight on AbbVie...
Monday, November 11, 2024
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- What's Going On With Bristol-Myers Squibb Shares Monday?
- This Is What Whales Are Betting On AbbVie
- AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
- Live On CNBC, Jim Lebenthal Announces Bought ...
- AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
- AbbVie shares are trading lower after the com...
- AbbVie Reports Phase 2 EMPOWER Trials For Emr...